AstraZeneca Pharma India to launch Datverzo for HER2‑negative breast cancer in November 2026
AstraZeneca Pharma India Limited announced that its new oncology drug Datverzo (datopotamab deruxtecan) will be commercially launched in India in November 2026. The drug received import and market permission from the Drugs Controller General of India on 17 December 2025. The company also disclosed a financial provision of ₹156.1 million for possible improvement charges and interest related to a municipal demand notice.
Why it matters
The ₹156.1 million provision may reduce the company’s reported earnings for the quarter in which it is recognized, according to the filing. The launch adds a new treatment option in the Indian breast‑cancer market, potentially expanding AstraZeneca’s sales base.
Key facts
- 1Import and market permission for Datverzo was received on 17 December 2025. businessupturn.com
- 2The commercial launch is scheduled for November 2026. businessupturn.com
- 3Datverzo is indicated for adult patients with unresectable or metastatic HR‑positive, HER2‑negative breast cancer. scanx.trade
- 4AstraZeneca Pharma India has made a provision of ₹156.1 million for potential charges and interest. scanx.trade
- 5The anticipated municipal improvement charge is up to ₹70.8 million, plus interest. scanx.trade
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.